Published in Acta Neuropathol on February 23, 2008
Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol (2008) 2.44
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol (2009) 1.73
The neuropathology of genetic Parkinson's disease. Mov Disord (2012) 1.73
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology (2012) 1.69
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Formation and development of Lewy pathology: a critical update. J Neurol (2009) 1.37
Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet (2010) 1.36
Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm (Vienna) (2010) 1.22
Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology (2009) 1.19
Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinsons Dis (2011) 1.13
The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun (2013) 1.11
Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol (2008) 1.10
Parkinson's disease dementia: a neural networks perspective. Brain (2015) 1.10
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Inflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link? Mol Neurobiol (2012) 1.04
Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging (2009) 1.04
Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol (2012) 1.01
α-Synuclein: the long distance runner. Brain Pathol (2013) 0.99
Pathogenesis of Parkinson disease-the gut-brain axis and environmental factors. Nat Rev Neurol (2015) 0.98
Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis (2011) 0.95
Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci (2014) 0.93
Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. J Parkinsons Dis (2011) 0.93
Can we clinically diagnose dementia with Lewy bodies yet? Transl Neurodegener (2013) 0.92
Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm (Vienna) (2014) 0.92
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol (2015) 0.92
Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89
Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol (2008) 0.88
The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther (2014) 0.88
Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem (2016) 0.88
Age and apoE associations with complex pathologic features in Alzheimer's disease. J Neurol Sci (2008) 0.87
Is synaptic loss a unique hallmark of Alzheimer's disease? Biochem Pharmacol (2014) 0.87
Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther (2014) 0.86
Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl Neurodegener (2012) 0.86
A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease. Alzheimers Res Ther (2014) 0.86
Clinico-pathological correlations of the most common neurodegenerative dementias. Front Neurol (2012) 0.86
Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) (2015) 0.85
Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathol (2015) 0.81
Advances in markers of prodromal Parkinson disease. Nat Rev Neurol (2016) 0.80
Complex network-driven view of genomic mechanisms underlying Parkinson's disease: analyses in dorsal motor vagal nucleus, locus coeruleus, and substantia nigra. Biomed Res Int (2014) 0.76
Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly. Alzheimers Res Ther (2015) 0.76
Exploring Braak's Hypothesis of Parkinson's Disease. Front Neurol (2017) 0.75
Bibenzyl compound 20c protects against endoplasmic reticulum stress in tunicamycin-treated PC12 cells in vitro. Acta Pharmacol Sin (2016) 0.75
Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. Front Neurol (2017) 0.75
Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. Surg Neurol Int (2017) 0.75
A novel computerized algorithm to detect microstructural brainstem pathology in Parkinson's disease using standard 3 Tesla MR imaging. J Neurol (2014) 0.75
Parkinson's disease as a multisystem disorder. J Neural Transm (Vienna) (2017) 0.75
Alpha-synuclein oligomers: a new hope. Acta Neuropathol (2017) 0.75
Embryonic development of selectively vulnerable neurons in Parkinson's disease. NPJ Parkinsons Dis (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci (2003) 8.44
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (2006) 8.15
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol (1999) 3.20
Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol (2000) 2.91
Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease? Clin Neuropathol (1985) 2.72
Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol (2006) 2.57
Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry (2003) 2.54
Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol (2000) 2.47
Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol (2002) 2.46
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem (2003) 2.42
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl (1993) 2.27
Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol (2005) 2.21
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17
Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol (2006) 1.87
Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology (2005) 1.82
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (2003) 1.58
Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol (2004) 1.41
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (2000) 1.41
Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. Acta Neuropathol (2003) 1.29
Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology (2006) 1.24
Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol (1998) 1.17
Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (2003) 1.15
Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.01
Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology (2005) 0.94
Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord (2004) 0.90
Linking SIRT2 to Parkinson's disease. ACS Chem Biol (2007) 0.90
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (2006) 8.15
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A (2008) 2.30
Association between blood pressure and survival over 9 years in a general population aged 85 and older. J Am Geriatr Soc (2006) 2.21
Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol (2005) 2.21
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging (2006) 1.96
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet (2010) 1.89
Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol (2010) 1.74
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol (2008) 1.55
Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J (2005) 1.54
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology (2005) 1.46
Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol (2003) 1.41
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol (2012) 1.33
The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am J Epidemiol (2015) 1.27
Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol (2003) 1.18
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord (2008) 1.17
Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization. J Pathol (2012) 1.16
Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging (2007) 1.15
Ubiquitinated p62-positive, TDP-43-negative inclusions in cerebellum in frontotemporal lobar degeneration with TAR DNA binding protein 43. Neuropathology (2009) 1.14
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol (2005) 1.14
Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol (2002) 1.14
Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. Int J Geriatr Psychiatry (2010) 1.13
TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol (2014) 1.08
Long-term epilepsy surgery outcomes in patients with MRI-negative temporal lobe epilepsy. Epilepsia (2010) 1.07
CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis (2008) 1.06
Postmortem examination of vascular lesions in cognitive impairment: a survey among neuropathological services. Stroke (2006) 1.05
A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem Biophys Res Commun (2008) 1.04
Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cells. J Neuroinflammation (2012) 1.03
Emerging role of p62/sequestosome-1 in the pathogenesis of Alzheimer's disease. Prog Neurobiol (2011) 1.02
Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. Stroke (2007) 1.02
Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol Dis (2005) 1.01
Fine mapping of a multiple sclerosis locus to 2.5 Mb on chromosome 17q22-q24. Hum Mol Genet (2002) 1.01
Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis (2010) 1.00
Cortical brain biopsy in long-term prognostication of 468 patients with possible normal pressure hydrocephalus. Neurodegener Dis (2012) 0.99
Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging (2005) 0.99
Prenatal diagnosis of placenta accreta and percreta with ultrasonography, color Doppler, and magnetic resonance imaging. Obstet Gynecol (2004) 0.98
Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. Neurobiol Dis (2006) 0.97
Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. Hum Mol Genet (2009) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis (2002) 0.95
Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry (2003) 0.95
Beta-amyloid aggregation in human brains with cerebrovascular lesions. Stroke (2006) 0.95
Glycosylation changes in Alzheimer's disease as revealed by a proteomic approach. Neurosci Lett (2004) 0.94
Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology (2005) 0.94
The effect of prolonged fixation time on immunohistochemical staining of common neurodegenerative disease markers. J Neuropathol Exp Neurol (2010) 0.94
Both N-methyl-D-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35 in cultured rat hippocampal neurons. Neurosci Lett (2004) 0.94
Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter-rater study. J Neuropathol Exp Neurol (2013) 0.93
Vascular risk factors and dementia in the general population aged >85 years: prospective population-based study. Neurobiol Aging (2008) 0.93
Cystatin C expression is associated with granule cell dispersion in epilepsy. Ann Neurol (2005) 0.92
TAR-DNA binding protein-43 and alterations in the hippocampus. J Neural Transm (Vienna) (2011) 0.91
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics (2008) 0.91
No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2007) 0.91
Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol (2011) 0.91
Cardiovascular diseases and hippocampal infarcts. Hippocampus (2011) 0.90
A follow-up study of chromosome 19q13 in multiple sclerosis susceptibility. J Neuroimmunol (2009) 0.90
An update on clinical proteomics in Alzheimer's research. J Neurochem (2009) 0.90
Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem (2007) 0.90
Perfusion and diffusion MRI combined with ¹¹C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas. J Neurooncol (2013) 0.88
CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neurosci Lett (2009) 0.88
A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival. Int J Cancer (2013) 0.88
Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus. Neurosurgery (2013) 0.87
Human postmortem brain tissue and 2-mm tissue microarrays. Appl Immunohistochem Mol Morphol (2006) 0.87
Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport (2004) 0.87
Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. J Neuroimmunol (2008) 0.87
Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. PLoS One (2011) 0.86
Distribution of collagen XVII in the human brain. Brain Res (2007) 0.86
Integration of expression profiles and genetic mapping data to identify candidate genes in intracranial aneurysm. Physiol Genomics (2007) 0.86
[Update on current care guidelines. The diagnosis and medical treatment of memory disorders]. Duodecim (2010) 0.86
Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients. Eur J Health Econ (2004) 0.85
Collagen XVII is expressed in human CNS neurons. Matrix Biol (2006) 0.85
GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients. J Alzheimers Dis (2013) 0.85
Analysis of human tau in cerebrospinal fluid. J Proteome Res (2010) 0.84
Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology (2013) 0.84
Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab (2013) 0.84
Heavy alcohol consumption and neuropathological lesions: a post-mortem human study. J Neurosci Res (2009) 0.84
Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure. Seizure (2009) 0.83
Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35. Brain Res Mol Brain Res (2002) 0.83